The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.
 
Robert L. Coleman
Consulting or Advisory Role - Clovis Oncology; DOD-CDRMP; Esperance Pharmaceuticals; Genentech/Roche; NCCN
Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Clovis Oncology; GOG Foundation; Merck; Millennium; New Mexico Cancer Center; Research to Practice; Roche/Genentech; University of California, Irvine; University of Cincinnati Cancer Center; University of Miami
 
Danielle Enserro
No Relationships to Disclose
 
Nick Spirtos
No Relationships to Disclose
 
Thomas J. Herzog
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Johnson & Johnson; Roche/Genentech; Tesaro
 
Paul Sabbatini
Honoraria - UpToDate
Research Funding - Bristol-Myers Squibb (Inst); Ludwig Institute for Cancer Research (Inst)
 
Deborah Kay Armstrong
Honoraria - AstraZeneca/MedImmune
Consulting or Advisory Role - CUE Biopharma
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (I); Exelixis (I); Medpace (Inst); Pfizer (Inst); Syndax (Inst); Tesaro (Inst)
 
Byoung Kim
No Relationships to Disclose
 
Keiichi Fujiwara
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen Oncology; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Joan L. Walker
No Relationships to Disclose
 
Patrick J. Flynn
Employment - ARIAD (I); Sanofi (I)
Stock and Other Ownership Interests - ARIAD (I)
Speakers' Bureau - Celgene; Lilly; Novartis; Teva
 
Angeles Alvarez Secord
Honoraria - Alexion Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Genentech/Roche; Janssen; Myriad Pharmaceuticals; Tesaro
Consulting or Advisory Role - Alexion Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Genentech/Roche; Janssen; Myriad Genetics; Tesaro
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Merck (Inst); Morphotek (Inst); PharmaMar (Inst); Prima BioMed (Inst); Tesaro (Inst)
 
David E. Cohn
No Relationships to Disclose
 
Mark F. Brady
Consulting or Advisory Role - Aeterna Zentaris; Cel-Sci; Endocyte
 
Robert S. Mannel
Consulting or Advisory Role - Clovis Oncology (Inst); Tesaro (Inst)